Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy

Trial Profile

Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Oct 2017

At a glance

  • Drugs Patritumab (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms HER3-Lung
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Oct 2016 This trial is completed in Hungary (End date: 18 May 2016), according to European Clinical Trials Database.
    • 31 May 2016 Status changed from recruiting to discontinued, according to a Daiichi Sankyo media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top